Bernhard Keppler talks to Uni:view about the progress ofmetal-based anticancer drugs, the latest development of KP46 and KP1339, the new compound Albuplatin and P4 Therapeutics, the joint reasearch cluster with the Medical University of Vienna and the importance of translational research.
- Metalle als Feinde des Tumors (Uni:view Magazin, 9.10.2019)
- Der Feind in der Tumorzelle (Kronzen Zeitung, 2.11.2019)
